Skip Ribbon Commands
Skip to main content

News

 

 

Terumo to Construct a New Manufacturing Facility at its Kofu Factory for the Medical Care Solutions Companyhttps://www.terumo-europe.com/en-emea/news/terumo-to-construct-a-new-manufacturing-facility-at-its-kofu-factory-for-the-medical-care-solutions-companyTerumo to Construct a New Manufacturing Facility at its Kofu Factory for the Medical Care Solutions CompanyTOKYO, JAPAN5/14/2023 10:00:00 PM<p>​52.2 Billion JPY Capital Investment to Strengthen the Production Capability to Meet the Growing Global Demands<br></p>
Ultimaster Nagomi™ MDR certification and launch of large-scale post-market study investigating the new coronary stent system in complex PCIhttps://www.terumo-europe.com/en-emea/news/ultimaster-nagomi™-mdr-certification-and-launch-of-large-scale-post-market-study-investigating-the-new-coronary-stent-systeUltimaster Nagomi™ MDR certification and launch of large-scale post-market study investigating the new coronary stent system in complex PCILEUVEN, BELGIUM4/25/2023 10:00:00 PM<p>​First patient enrolled in the NAGOMI COMPLEX PMCF study <br></p>
Terumo Group’s Targets for Greenhouse Gas Reduction Approved by the SBT Initiative as 1.5°C Alignedhttps://www.terumo-europe.com/en-emea/news/terumo-group’s-targets-for-greenhouse-gas-reduction-approved-by-the-sbt-initiative-as-1-5°c-alignedTerumo Group’s Targets for Greenhouse Gas Reduction Approved by the SBT Initiative as 1.5°C AlignedTOKYO, JAPAN4/23/2023 10:00:00 PM<p>Terumo Corporation (TSE: 4543) today announced that its greenhouse gas (GHG) emissions reduction targets have been approved by the Science Based Targets initiative (SBTi) as being aligned with the common goal to limit global temperature rise to 1.5°C above pre-industrial levels.​<br></p>
Terumo to Further Drive DE&I by Establishing Focus Areas to Commit Globallyhttps://www.terumo-europe.com/en-emea/news/terumo-to-further-drive-de-i-by-establishing-focus-areas-to-commit-globallyTerumo to Further Drive DE&I by Establishing Focus Areas to Commit GloballyTOKYO, JAPAN3/1/2023 11:00:00 PM<p>​Terumo Corporation (TSE: 4543) today announced that it will further drive its initiatives to promote a culture of diversity, equity, and inclusion (DE&I) as a Group. The company has newly selected four focus areas it will commit on a global scale. <br></p>
Ultimaster Drug Eluting Stent family (Terumo) first stent to receive the mention 1-month DAPT in the reimbursement conditions in Francehttps://www.terumo-europe.com/en-emea/news/ultimaster-drug-eluting-stent-family-first-stent-to-receive-the-mention-1-month-dapt-in-the-reimbursement-conditions-in-frUltimaster Drug Eluting Stent family (Terumo) first stent to receive the mention 1-month DAPT in the reimbursement conditions in FranceLEUVEN, BELGIUM12/7/2022 11:00:00 PM<h4>​Terumo Europe is proud to announce that the HAS (Haute Autorité de Santé) in France has acknowledged in an evidence-based assessment that for the <strong>Ultimaster</strong><sup><strong>TM</strong></sup> and <strong>Ultimaster</strong><sup><strong>TM</strong></sup> <strong>Tansei</strong><sup><strong>TM</strong></sup> stents dual antiplatelet therapy (DAPT) can safely be stopped <strong>after 1 month for High Bleeding Risk patients</strong>. This conclusion is based on the strong and unmatched clinical data generated in the MASTER DAPT study and hence superiority of shortened DAPT regimen can only be attributable and linked to the <strong>Ultimaster</strong><sup><strong>TM</strong></sup> stent.<br><br></h4>